Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure
Tóm tắt
Từ khóa
Tài liệu tham khảo
Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007;46:254–65.
Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003;36:687–96.
Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527–32.
Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol 2006;44:422–31.
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352:2673–81.
Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006;43:1385–91.
Perrillo RP. Current treatment of chronic hepatitis B: benefits and limitations. Semin Liver Dis 2005;25 Suppl 1:20–8.
Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006;44:1656–65.
Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003;125:292–7.
Van Bommel F, Zollner B, Moller B, Huppe D, Feucht H-H, Wiedenmann B, et al. Is tenofovir effective in treatment of adefovir resistant hepatitis B virus (HBV) infections [Abstract 1016]? Hepatology 2006;44 4 Suppl 1:567A.
Suzuki F, Akuta N, Suzuki Y, Yatsuji H, Sezaki H, Arase Y, et al. Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H. J Clin Virol 2007;39:149–52.
Torresi J, Earnest-Silveira L, Deliyannis G, Edgtton K, Zhuang H, Locarnini S, et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002;293:305–13.
Warner N, Locarnini S. The multi-drug resistant hepatitis B virus rtA181T has a secretion defect and significantly reduces the kinetics of viral rebound. Hepatology 2007; in press.